These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646 [TBL] [Abstract][Full Text] [Related]
5. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219 [TBL] [Abstract][Full Text] [Related]
6. A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark. Hvelplund T; Lange B; Bird SD; Korsholm M; Kjeldsen AD Orphanet J Rare Dis; 2022 Jan; 17(1):8. PubMed ID: 34991676 [TBL] [Abstract][Full Text] [Related]
7. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Eker OF; Boccardi E; Sure U; Patel MC; Alicante S; Alsafi A; Coote N; Droege F; Dupuis O; Fialla AD; Jones B; Kariholu U; Kjeldsen AD; Lefroy D; Lenato GM; Mager HJ; Manfredi G; Nielsen TH; Pagella F; Post MC; Rennie C; Sabbà C; Suppressa P; Toerring PM; Ugolini S; Buscarini E; Dupuis-Girod S; Shovlin CL Orphanet J Rare Dis; 2020 Jun; 15(1):165. PubMed ID: 32600364 [TBL] [Abstract][Full Text] [Related]
8. The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. Shovlin CL; Buscarini E; Sabbà C; Mager HJ; Kjeldsen AD; Pagella F; Sure U; Ugolini S; Torring PM; Suppressa P; Rennie C; Post MC; Patel MC; Nielsen TH; Manfredi G; Lenato GM; Lefroy D; Kariholu U; Jones B; Fialla AD; Eker OF; Dupuis O; Droege F; Coote N; Boccardi E; Alsafi A; Alicante S; Dupuis-Girod S Eur J Med Genet; 2022 Jan; 65(1):104370. PubMed ID: 34737116 [TBL] [Abstract][Full Text] [Related]
9. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517 [TBL] [Abstract][Full Text] [Related]
13. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391 [TBL] [Abstract][Full Text] [Related]
14. [Osler's disease - a disease with a wide variety of clinical manifestations deserving multidisciplinary competence]. Rönnblom A; Ellingsen J; Frykholm C; Karlsson T; Larsson B; Nelander M; Rorsman F; Thor A; Lidian A Lakartidningen; 2022 Aug; 119():. PubMed ID: 36082917 [TBL] [Abstract][Full Text] [Related]
15. Hereditary haemorrhagic telangiectasia: a cause of preventable morbidity and mortality. Brady AP; Murphy MM; O'Connor TM Ir J Med Sci; 2009 Jun; 178(2):135-46. PubMed ID: 18923886 [TBL] [Abstract][Full Text] [Related]
16. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment. Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review. Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788 [TBL] [Abstract][Full Text] [Related]
18. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Epperla N; Hocking W Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223 [TBL] [Abstract][Full Text] [Related]
19. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841 [TBL] [Abstract][Full Text] [Related]
20. [Implementation and development of a center for hereditary hemorrhagic telangiectasia]. Droege F; Dingemann J; Thangavelu K; Kuerten CHL; Dahlfrancis PM; Kaiser C; Kaster F; Zioga E; Meyer C; Lueb C; Sure U; Lang S; Geisthoff U Laryngorhinootologie; 2021 May; 100(5):372-381. PubMed ID: 33723832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]